A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients With Advanced Solid Tumors

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-06-2250
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora a Kinase Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2012English

A Phase I Pharmacokinetic and Pharmacodynamic Study of the Farnesyl Transferase Inhibitor BMS-214662 in Combination With Cisplatin in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2004English

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

A Phase IB Trial of 24-Hour Intravenous PX-12, a Thioredoxin-1 Inhibitor, in Patients With Advanced Gastrointestinal Cancers

Investigational New Drugs
OncologyPharmacology
2012English

Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2015English

A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients With Advanced Solid Tumors and Liver Metastases

Clinical Cancer Research
Cancer ResearchOncology
2014English

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor With a Heat Shock Protein-90 Inhibitory Profile, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2008English

First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2020English

A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative With Polo-Like Kinase-1-Interacting Properties, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy